LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq 21:00:00 20/11/2025 GMT			5-day change	1st Jan Change
1.740 ^USD	-3.87%		-.--%	-

11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE

Market Cap	45.77M 39.57M 37.22M 33.82M 63.5M 4.37B 64.61M 436M 170M 2.19B 172M 168M 7.29B	P/E 2023	-1.01x	P/E 2024	-1.02x
Enterprise Value	-25.52M -22.07M -20.76M -18.86M -35.41M -2.44B -36.03M -243M -94.95M -1.22B -95.79M -93.74M -4.07B	EV / Sales 2023	-7,049,969x	EV / Sales 2024	-3,862,875x
Free-Float	83.62%	Yield 2023 *	-	Yield 2024	-

11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE
11-20	LAVA Therapeutics N.V.(NasdaqGS:LVTX) dropped from NASDAQ Composite Index	CI
11-19	XOMA Royalty Corporation completed the acquisition of LAVA Therapeutics N.V..	CI
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
11-06	LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
17/10/25	XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline	MT
17/10/25	Xoma Royalty and Lava Therapeutics announce amendment to purchase agreement	RE
02/10/25	XOMA Royalty Extends Tender Offer to Acquire Lava Therapeutics	MT
13/08/25	LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/08/25	LAVA Therapeutics N.V. Plans to Discontinue LAVA-1266 Program	CI
05/08/25	Jefferies Downgrades LAVA Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $3	MT
04/08/25	XOMA Royalty Corporation entered a definitive share purchase agreement to acquire LAVA Therapeutics N.V..	CI

11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
05/08/25	Jefferies Downgrades LAVA Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $3	MT
27/02/25	HC Wainwright Downgrades LAVA Therapeutics to Neutral From Buy, Adjusts Price Target to $1.50 From $2	MT
12/12/24	Leerink Partners Downgrades LAVA Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2 From $11	MT
11/12/24	JMP Securities Downgrades LAVA Therapeutics NV to Market Perform From Market Outperform	MT

LAVA Therapeutics Share Price

Stocks

LVTX

NL0015000AG6

Biotechnology & Medical Research

Valuation: LAVA Therapeutics

Chart: LAVA Therapeutics

Latest news : LAVA Therapeutics

Analysts' recommendations: LAVA Therapeutics

Press Releases: LAVA Therapeutics

Quotes and Performance

Course Extremes

Managers and Directors: LAVA Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

11-21	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.	AQ
11-13	LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq	AQ
11-10	LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline	AQ
17/10/25	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement	AQ
02/10/25	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.	AQ

Manager	Title	Age	Since
Jessica Truscello CTO	Chief Tech/Sci/R&D Officer	-	08/11/2021
Robin Hume LAW	General Counsel	-	14/05/2023
Wouter van Hunnik HRO	Human Resources Officer	-	08/11/2021

Director	Title	Age	Since
Kapil Dhingra CHM	Chairman	66	21/02/2021
Karen Wilson BRD	Director/Board Member	62	28/02/2021
Owen Hughes BRD	Director/Board Member	51	06/11/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
13/11/25	Stephen Hurly	Issuer sale	Chief Executive Officer	340,100	1.2929%
13/11/25	Fred Powell	Issuer sale	Chief Financial Officer	189,700	0.7211%
13/11/25	Mary Wadlinger	Issuer sale	Director	33,390	0.1269%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVA THERAPEUTICS	-3.87%	-.--%	+14.47%	-3.33%	45.77M
LONZA GROUP AG	-1.78%	-1.68%	+1.48%	+15.31%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+563.55%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+71.41%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+8.73%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+49.65%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+118.09%	16.15B
EUROFINS SCIENTIFIC SE	+0.49%	+0.92%	+4.11%	+23.67%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+33.31%	13.37B
Average	-0.99%	+0.44%	+70.96%	+97.82%	26.32B
Weighted average by Cap.	-0.91%	+0.59%	+95.81%	+132.92%

	2023	2024
Net sales	6.77 5.85 5.5 5 9.39 645.86 9.56 64.41 25.18 323.74 25.4 24.86 1.08K	11.98 10.36 9.74 8.85 16.62 1.14K 16.91 114.02 44.57 573.05 44.97 44.01 1.91K
Net income	-41.97M -36.29M -34.13M -31.02M -58.23M -4B -59.25M -399M -156M -2.01B -158M -154M -6.69B	-25.11M -21.71M -20.42M -18.56M -34.84M -2.4B -35.45M -239M -93.43M -1.2B -94.25M -92.24M -4B
Net Debt	-89.26M -77.17M -72.59M -65.96M -124M -8.52B -126M -849M -332M -4.27B -335M -328M -14.22B	-71.3M -61.64M -57.98M -52.69M -98.9M -6.8B -101M -678M -265M -3.41B -268M -262M -11.36B

1 year	1.4	1.82
3 years	0.85	6.47
5 years	0.85	8.38
10 years	0.85	17.2